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Health-related quality of life from the MM-003 trial
of pomalidomide plus low-dose dexamethasone 
versus high-dose dexamethasone in relapsed 
and/or refractory multiple myeloma
Advances in treatments for multiple myeloma (MM)
have resulted in improved survival. However, patients who
have become refractory to novel agents have a poor prog-
nosis, with a median overall survival (OS) of nine months,
or as low as three months in the absence of further treat-
ment after failure of regimens including bortezomib
(BORT), thalidomide (THAL) or lenalidomide (LEN).1 After
multiple lines of therapy, the health-related quality of life
(HRQoL) of patients with relapsed and/or refractory MM
(RRMM) is often compromised,2with impairments in phys-
ical, emotional, social and cognitive functioning.3
Pomalidomide (POM) was recently approved in the US
and Europe in combination with dexamethasone for use in
patients with RRMM who have received at least two prior
treatment regimens, including both LEN and BORT, and
have demonstrated disease progression on their last thera-
py. In the pivotal MM-003 trial, POM+LoDEX provided
significant and clinically meaningful improvements in pro-
gression-free survival (PFS) and OS compared with high-
dose dexamethasone (HiDEX), a commonly used salvage
treatment for heavily pre-treated patients at the time the
study was initiated.4 MM-003 was the first study to inves-
tigate HRQoL in RRMM patients receiving POM. Here, we
present HRQoL results of cross-sectional and longitudinal
analyses that were included as pre-specified secondary end
points. 
The design of MM-003 has been reported previously4
and is summarized in Figure 1. Enrolled patients were
refractory to their last treatment and had failed BORT and
LEN after at least two cycles of each (alone or in combina-
tion). Patients progressing on HiDEX were allowed to
receive POM in a companion MM-003C trial (Figure 1);
these patients were not included in the HRQoL analysis
after progression from their trial regimen. 
Three HRQoL instruments that have been validated pre-
viously in MM patients5 were included as pre-defined end
points for non-progressing patients and scored according to
their user manuals: the European Organisation for Research
and Treatment of Cancer (EORTC) QLQ-C30, EORTC
QLQ-MY20, and EQ-5D. The analysis focused on eight
pre-selected domains chosen following a workshop discus-
sion with specialists on perceived clinical relevance and on
results of multivariate regression analysis comparing
domains with the EQ-5D utility index.6 The domains
included five from EORTC QLQ-C30 (Global Health
Status, Physical Functioning, Emotional Functioning,
Fatigue, and Pain), two from EORTC QLQ-MY20 (Disease
Symptoms, Side Effects of Treatment), and the EQ-5D
Health Utility value (mapped to a scale with 1 = best health
state and 0 = death using a time trade-off methodology).
Patients completed HRQoL questionnaires at baseline,
on day 1 of each treatment cycle, and at discontinuation.
HRQoL scores were calculated from baseline through to
cycle (C) 10 in the cross-sectional analyses. Later cycle data
were limited in value due to few remaining patients.
Intention-to-treat (ITT) subjects with at least one HRQoL
measurement in this period were included in the analyses. 
We compared changes in HRQoL scores from baseline
and between treatment arms at each cycle by cross-section-
al and longitudinal analyses. Cross-sectional descriptive
and comparative (between and within treatment arms)
analyses used domain scores analyzed as continuous vari-
ables. Longitudinal repeated measure mixed effects models
were generated to estimate the treatment effect on HRQoL
over time and between treatment arms, and adjusted
means of score differences from baseline were calculated.
Of the 455 ITT subjects, 433 completed HRQoL meas-
urements and were included in this analysis (POM+LoDEX
n=289; HiDEX n=144). Median patient age was 64 years,
and over 94% (410/433) had received more than 2 prior
therapies; 82% (355 of 433) were refractory to LEN and
BORT. Median follow up was ten months. There was no
significant difference in patients’ base-line demographics
and disease-related characteristics between arms.4
Of the 289 patients randomized to receive
POM+LoDEX, 17.6% (51 of 289) had EORTC QLQ-C30
and QLQ-MY20 available data at C10 versus 5.5% (8 of
144) of HiDEX patients; 17.3% (50 of 289) of
POM+LoDEX patients had EQ-5D data available at C10
versus 4.8% (7 of 144) of HiDEX patients.
Compliance rates up to C10 were generally high
(≥77.8% of presenting patients across cycles) and were
consistent between treatment groups. Due to the progres-
sive nature of MM, the number of participating patients
dropped as the study progressed. Patients in the HiDEX
group discontinued from the study earlier than those in the
POM+LoDEX group.4 Reasons for discontinuation were
comparable between treatment arms.
In the cross-sectional analysis, mean score improved sig-
nificantly from baseline (P<0.05, paired t-test) in the
POM+LoDEX arm for the Health Utility domain, and dete-
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Figure 1. Trial design. aProgression
of disease was independently adju-
dicated in real time. bHiDEX was
chosen as comparator because at
the time of trial design it was the
standard salvage therapy for heavi-
ly pre-treated patients. D: days;
HiDEX: high-dose dexamethasone;
LoDEX: low-dose dexamethasone;
OS: overall survival; PD: progressive
disease; POM: pomalidomide;
SPM: second primary malignancy.   
riorated significantly from baseline for Side Effects of
Treatment. In the HiDEX arm, no domains showed
improvement, and 5 showed deterioration from baseline:
Physical Functioning, Health Utility, Fatigue, Disease
Symptoms, and Side Effects of Treatment (Figure 2, indicat-
ed by ‡). 
Between treatment groups, significant differences
(P<0.05, unpaired t-test) in favor of POM+LoDEX were
observed in five of the eight pre-selected domains (Physical
Functioning, Emotional Functioning, Health Utility,
Fatigue, and Side Effects of Treatment) at specific treatment
cycles (Figure 2, indicated by *). Trends (P<0.1, unpaired t-
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Figure 2. Cross-sectional analysis of mean HRQoL score changes from baseline per treatment cycle. *P<0.05 unpaired t-test comparing
the two treatment groups from baseline; ‡P<0.05 paired t-test (within group mean change from baseline).
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Figure 3. Repeated measure mixed model score changes from baseline (adjusted means). P values indicate unpaired t-test comparing
treatment groups. *Significant P value (P<0.05).
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test) in favor of POM+LoDEX were observed at specific
time points for the Health Utility, Fatigue, and Disease
Symptoms domains. HiDEX treatment was not superior to
POM+LoDEX in any domain. Results of subgroup analyses
in patients aged over 75 years and 75 years or under were
consistent with the overall findings.
To understand how the HRQoL progressed with time we
performed longitudinal analyses using repeated measure
mixed-effect models. There were significant (P<0.05) over-
all treatment differences between POM+LoDEX and
HiDEX over the course of treatment in seven of the eight
pre-selected clinically relevant domains: Global Health
Status (P=0.0451), Physical Functioning (P<0.0001),
Emotional Functioning (P=0.0003), Health Utility
(P=0.005), Fatigue (P=0.0008), Pain (P=0.0049), and Side
Effects of Treatment (P=0.0253). Only Disease Symptoms
did not demonstrate a significant difference. Comparisons
of adjusted means of score differences from baseline
between treatment arms at each cycle confirmed the supe-
riority of POM+LoDEX treatment arm in these seven
domains (Figure 3). 
We show that in heavily pre-treated RRMM patients
who failed BORT and LEN, POM+LoDEX not only results
in significantly better clinical outcomes, but also in signifi-
cantly better HRQoL compared with HiDEX treatment.4
The cross-sectional analyses show that across key clini-
cally relevant HRQoL domains associated with MM,
patients on POM+LoDEX had better HRQoL during the
first 10 treatment cycles compared with those receiving
HiDEX. The significant within-group improvement from
baseline over the course of treatment in Health Utility for
POM+LoDEX patients and the significant deteriorations
from baseline observed in the HiDEX arm in the Physical
Functioning, Health Utility, Fatigue, Disease Symptoms,
and Side Effects of Treatment domains, as well as signifi-
cant between-group differences in favor of POM+LoDEX
in the Physical Functioning, Emotional Functioning, Health
Utility, Fatigue, and Side Effects of Treatment domains at
given cycles indicate better HRQoL among patients on
POM+LoDEX versus HiDEX. There was no significant
worsening of scores from baseline in the POM+LoDEX arm
for 7 of the 8 pre-selected domains, indicating that
POM+LoDEX does not adversely affect HRQoL.
Maintenance of HRQoL is a benefit in this late line popula-
tion with limited treatment options. There was no demon-
stration of worsening with POM, while treatment with
HiDEX did show worsening of HRQoL.
The repeated measure mixed-model longitudinal analy-
sis across time points confirmed the significant difference in
score changes from baseline favoring the POM+LoDEX ver-
sus the HiDEX arm over the course of treatment for seven
of the eight evaluated domains, despite cross-sectional
results at individual cycles. 
These findings, together with the primary efficacy results
of the MM-003 trial, demonstrate that POM+LoDEX is a
safe and effective treatment option for RRMM that does
not negatively affect HRQoL, and offers improved HRQoL
in key domains versus HiDEX. Given that even minor
changes in patient-related outcomes may have long-term
implications for RRMM patients, these results are meaning-
ful.
Our approach to evaluate HRQoL is consistent with prior
studies of novel oral anti-myeloma therapies and dexam-
ethasone in RRMM,7-9 and is strengthened by considering
HRQoL changes over time, the regular timing of assess-
ments, and the randomized study design. It should, how-
ever, be borne in mind that the MM-003 study was pow-
ered to detect differences in PFS rather than pre-specified
HRQoL end points. 
There are adverse events associated with HiDEX that can
negatively affect HRQoL. POM+LoDEX did not show a
deterioration of HRQoL for 7 of 8 analyzed domains
despite this regimen containing two agents compared to
single agent HiDEX. 
In heavily pre-treated RRMM patients with end-stage
disease, maintaining HRQoL may be an important clinical
decision factor. The HRQoL domains evaluated here are
directly related to quality of survival, and may be helpful in
making treatment decisions.10-12 Response in MM patients
should not be the unique outcome; other end points, such
as safety and HRQoL must also be considered, as some
patients may derive greater benefit from a lower level of
response while achieving prolonged survival without facing
unnecessary risk.13 
POM+LoDEX has become a standard of care treatment
in the US for relapsing patients who have received LEN and
BORT, and has seen rapid uptake in European countries
since its introduction.14 We show that this treatment com-
bination leads to significant HRQoL improvements that
could potentially enhance the lives of patients with
RRMM.
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